key: cord-0983557-6x2n8ue8
authors: Freeman, Coral; Duan, Eugene; Kessler, Jack
title: Molecular iodine is not responsible for cytotoxicity in iodophors
date: 2022-02-04
journal: J Hosp Infect
DOI: 10.1016/j.jhin.2022.01.015
sha: 92c44e1eb154c9a03d4a45e500edbb0c8c1fd72f
doc_id: 983557
cord_uid: 6x2n8ue8

BACKGROUND: Ten percent polyvinylpyrrolidone-iodine (PVP-I) was initially promoted as “tamed iodine” since the chemical activity of the active biocide, uncomplexed or free molecular iodine (I(2)), is reduced thirty to fifty-fold as compared to Lugol’s solution. The idea that I(2) is responsible for topical iodine staining and irritation remains widely held [1, 2]. However, there are no controlled studies that characterize the cytotoxicity and staining of the hydrophobic I(2) species as compared to the other hydrophilic iodine species that comprise over 99.9% of the total iodine in topical iodine disinfectants. AIM: The aims of investigation are to compare (a) the staining properties of the I(2) species versus other topical iodine disinfectants (b) to evaluate if the concentrations of I(2) in diluted PVP-I used to reduce SARS-CoV-2 in the nasal cavity are potentially cytotoxic and (c) determine if high concentrations of I(2) can be delivered beyond the stratum corneum into the hypodermis which could provide a mechanistic rationale for I(2) out-gassing first reported by Gottardi [3]. METHODS: Five liquid compositions that contained complexed and uncomplexed (free) I(2) in aqueous and non-aqueous carriers were used to evaluate the interaction of I(2) with mammalian cells in culture as well as human and pig skin. FINDINGS: Concentrations of I(2) (7800 ppm) that are 1500 times higher than that found in PVP-I can be applied to skin without irritation and staining. I(2) is not cytotoxic at concentrations more than 100 times higher than that found in PVP-I and does not materially contribute to staining of skin at concentrations found in Lugol’s solution (ca 170 ppm). I(2) can partition into hypodermis tissue, remains there for hours and out-gases from skin. PVP-I and Lugol’s solution are highly effective topical disinfectants but do not facilitate diffusion of I(2) through the stratum corneum. CONCLUSION: The maximum concentration of I(2) found in diluted PVP, about 25 ppm, is not cytotoxic or irritating. The potential clinical utility of I(2) has been limited by incorporating this broad-spectrum biocide in acidic aqueous formulations that contain numerous chemical species that contribute toxicity but not biocidal activity. I(2) can be delivered topically into hypodermis tissue without irritation.

The global pandemic has induced clinicians to identify agents that that can be used in the oral and nasal 55 cavities [4] [5] [6] [7] [8] [9] . Use of an I2 disinfectant is logical as (a) iodine has an established anti-viral and anti-56 microbial activity, (b) there is no evidence that bacteria can develop resistance to I2 [10, 11] since it 57 reacts with several functional groups thus providing simultaneous action against multiple molecular 58 targets, (c) I2 is a naturally occurring biomolecule synthesized in the follicular lumen and other iodine 59 concentrating tissues and (d) has a two-hundred-year use history in and on humans. The nose is the 60 primary nidus of infection for SARS-CoV-2 and while masks mitigate aerosol spread, they do nothing to 61 reduce viral load in the nasal cavity [12, 13] . The 3M™ Skin and Nasal Antiseptic is 5,000 ppm available 62 iodine iodophor that is painted onto the nasal cavity prior to surgery [14] and many clinicians have 63 advocated for use of a diluted iodophor solutions with 0.25%-1.5% thiosulphate titratable as a 64

prophylactic nasal lavage [15] [16] [17] [18] [19] for health care personnel. FDA has reviewed at least 27 clinical trials 65 that use diluted povidone iodine [20] to control Covid-19. Oral and nasal application of diluted PVP-I 66 nasal spray and irrigation [21, 22] has been adopted and products with lower total iodine concentrations 67 are also offered for this purpose (ioShield Nasal Barrier Cream, Iotech International, Boca Raton, FL; 68

Halodine Nasal Antiseptic, Miami, FL). 69

The thiosulphate titratable iodine in PVP-I can vary from the amount stated on the label by 35% since 71 the USP definition requires not less than 85.0 percent and not more than 120.0 percent of the labelled 72 amount of iodine [23] . The term "iodine" in this sentence means thiosulphate titratable iodine. 73

However, triiodide, hypoiodous acid and I2 are all reduced by thiosulphate and the concentration of 74 active biocide in PVP-I is 0.02-0.06% of the label claim. In addition, there is up to 6.6% iodide ion in PVP-75 I. Consequently, clinicians do not know the concentration of active biocide in the iodophor they use 76 generate a "low concentration" iodine disinfectant which can have a ten-fold higher concentration of 78 active biocide, i.e. I2 [24] . 79 80 Gottardi made the surprising discovery that topically applied I2 can diffuse into skin and provide a 81 prolonged (> 12 h duration) epidermal antibacterial activity due to a continuous flux or "back diffusion" 82 of absorbed I2 from skin [3] . Dilution of an iodophor like PVP-I results in an increase of I2 concentration 83 [25] [26] [27] that also increases absorption of I2 into skin as I2 flux is proportional to exposure time and 84 concentration. The interaction of PVP-I with skin and wounds has been extensively studied but these 85 studies do not provide insight into the interaction of the I2 species with skin. Only a limited number of 86 studies examine the topical properties of pure I2. Duan published acute dermal toxicity results for a low 87 concentration (35 ppm) I2 composition [28] and Uchiyama examined the efficacy of a 400 ppm I2 88 composition to reduce MRSA in the nasal carriage of mice [29] . In this study we compare the interaction 89 of I2 with skin using (a) I2-glycerine compositions and (b) several commercially available aqueous iodine The DPD reagent was removed after a defined contact time that ranged from 30 seconds to 15 minutes, 138 transferred to a cuvette and the absorbance was determined at 550 nm (Persee Analytics, Inc.; model 139 T6V). Pig skin was rinsed with two 1 ml DI-water rinses between DPD sampling to avoid cross-140 contamination. The I2 flux in µg/cm 2 -minute was determined by comparing the absorbance of unknowns 141 to a standard curve prepared daily. The between-day mean (N=25) and standard deviation of the slope 142 and intercept for the standard curve was 0.05217 A/ µg ± 0.00236 and 0.01163 A ± 0.00959 respectively. (Table I) which compares to about 10,000 µg of total iodine from PVP-I for an equivalent volume. However, a 239 much higher percentage of the iodine in I2-glycerine may be absorbed as compared to PVP-I. 240

Braverman's laboratory evaluated thyroid status during daily vaginal douching with 241 polyvinylpyrrolidone-iodine (0.3% thiosulphate titratable iodine) in twelve euthyroid volunteers for 14 242 days and concluded that 5% of the applied iodine was absorbed [46] . It is known that the concentration of I2 increases as PVP-I is diluted up about 1/100 [25] . Diluted PVP-I 271 has been shown to be less cytotoxic than neat PVP-I, therefore the literature provides indirect evidence 272 that I2 is not the cytotoxic species in PVP-I. Additionally, cadexomer iodine which contains a high 273 concentration of I2 as compared to 10% PVP-I does not affect fibroblast viability and collage synthesis. In 274 fact, cadexomer iodine stimulated secretion of proinflammatory cytokines (tumour necrosis factor-alpha 275 or TNF-a) in human macrophages [25] . 276

The characterization of PVP-I on product labels is not sufficient to ensure consistent results in cell-based 278 cytotoxicity studies due to variations in, pH (can very between 1.5 and 6.5), iodide concentration, ionic 279 strength, buffering capacity and I2 concentration [26, 27] . Additionally, there is a 15% variance allowed 280 in the level of titratable iodine under the definition in the USP. There is a legitimate concern that 281 formulation variations among different PVP-I compositions (manufacturer-to-manufacturer and lot-to-282 lot) have influenced cytotoxicity study outcomes unbeknownst to researchers conducting these studies 283 [31, 52, 53] . Equally problematic are studies that dilute a topical iodine composition and draw incorrect 284 conclusions based on the assumption that I2 is stable for days after dilution iodide/hr into I2 in a volume of about 7.5 ml which equates to generating 900 ppm I2/hr which is about 2 296 orders of magnitude higher than the I2 concentration found in PVP-I. Molecular iodine is the only widely 297 used disinfectant molecule that plays an essential role in mammalian biochemistry [75] and, if 298 formulated properly, can be used clinically at highly elevated concentrations. 299 300 Conclusion 301

The highest concentration of I2 achievable from diluted PVP-I is about 25 ppm which suggests that there 303 is at least a sixty-fold margin of safety for I2 with respect to topical toxicity on human mucous 304 membranes of the nasal cavity as a 1500 ppm I2 composition was adjudged to be not cytotoxic. The 305 staining and irritation associated with topical iodine disinfectants is not due to the I2 species. There are 306 potential clinical benefits that may accrue from the use of high concentrations of topically applied I2. 307 

WHO Guidelines on Hand Hygiene in Health Care: First Global Patient Safety Challenge Clean 315

Care Is Safer Care. WHO

Bactericidal activity 317 and toxicity of iodine-containing solutions in wounds

The uptake and release of molecular iodine by the skin: chemical and bactericidal 320 evidence of residual effects caused by povidone-iodine preparations

Review of the use of 323 nasal and oral antiseptics during a global pandemic

Povidone Iodine: Can it have a Preventive Role Against SARS-CoV-2 Infection Gateway?

Iodine Nasal and Oral Antiseptic Preparations Against Severe Acute Respiratory Syndrome-Coronavirus 2 330 (SARS-CoV-2)

Topical Ocular Povidone-Iodine as an Adjunctive Preventative Practice in 333 the Era of COVID-19

Methods to disinfect and 336 decontaminate SARS-CoV-2: a systematic review of

Gargle, and Nasal Spray to Reduce Nasopharyngeal Viral Load in Patients With COVID-19: A 340 Randomized Clinical Trial

Nondevelopment of resistance by bacteria during 343 hospital use of povidone-iodine

Absence of bacterial resistance to povidone iodine

COVID-19 Vaccines May Not Prevent Nasal SARS-CoV-2 348 Infection and Asymptomatic Transmission

354 [14] The evidence is mounting for 3M™ skin and nasal antiseptic [povidone-iodine solution 5% w/w 355 (0⋅5%available iodine) USP] preoperative skin preparation: five new studies prove clinical efficacy in 356 reducing the risk of surgical site infections

Consideration of povidone-iodine as 359 a public health intervention for COVID-19: Utilization as "Personal Protective Equipment" for frontline 360 providers exposed in high-risk head and neck and skull base oncology care

Iodine Nasal and Oral Antiseptic Preparations Against Severe Acute Respiratory Syndrome-Coronavirus 2 364 (SARS-CoV-2)

Considerations for povidone-iodine antisepsis in pediatric nasal 367 and pharyngeal surgery during the COVID-19 pandemic

Povidone-Iodine Use in Sinonasal and Oral Cavities: A 370 Review of Safety in the COVID-19 Era

Povidone Iodine (PVP-I) Oro-Nasal Spray: An Effective Shield for COVID-19 Protection 373 for Health Care Worker (HCW), for all

Povidone-Iodine Nasal Spray on Nasopharyngeal SARS-CoV-2 Viral Load: A Randomized Control Trial. The 380 Laryngoscope

Efficacy of Povidone-Iodine Nasal Irrigation 382 Solution After Sinonasal Surgery: A Randomized Controlled Study. The Laryngoscope 2021

Chemical Considerations Related to The Dilution of Commercial 10% Povidone-Iodine 387 For Use In The COVID-19 Pandemic

Increased bactericidal activity of dilute preparations of 389 povidone-iodine solutions

Comparison of free and bound iodine and 392 iodide species as a function of the dilution of three commercial povidone-iodine formulations and their 393 microbicidal activity

Comparison of free iodine as a function of the dilution 395 of two commercial povidone-iodine formulations

Properties of an enzyme-based 397 low-level iodine disinfectant

Biological evaluation of medical devices -Part 5: Tests for in vitro 402 cytotoxicity. Internation Organization for Standardization

Study of the toxicity of povidone-lodine for fibroblast-405 like cells (BALB-3T3)

Comparison of toxicity induced by iodine and iodide in male and 408 female rats

Differences in the distribution of iodine and iodide in the Sprague-Dawley rat

Distribution of iodine into blood components of the Sprague-Dawley 412 rat differs with the chemical form administered

Inhibition of N-415 methyl-N-nitrosourea-induced mammary carcinogenesis by molecular iodine (I2) but not by iodide (I-) 416 treatment Evidence that I2 prevents cancer promotion

Uptake and antiproliferative effect of molecular iodine in the MCF-7 breast 419 cancer cell line

Iodine and Iodine Compounds

Excipients and additives: hidden hazards in drug products and in product 423 substitution

The activities of drug 426 inactive ingredients on biological targets

The distribution of glycogen and lipids in human skin

Molecular iodine/polymer complexes

Danger of iodine skin absorption in the neonate

Effectiveness of skin absorption of 435 tincture of I in blocking radioiodine from the human thyroid gland

125I uptake competing with iodine absorption by the thyroid 438 gland following povidone-iodine skin application

Larese Filon F. Povidone iodine skin absorption: an ex-vivo 441 study

Effect of chronic douching with polyvinylpyrrolidone-iodine on iodine 443 absorption and thyroid function

Reassessment of the surgical scrub. Surgery, gynecology & 446 obstetrics

Hand disinfection: a comparison of various agents in 448 laboratory and ward studies

The evaluation of residual antimicrobial activity on hands and its clinical 451 relevance

Comparative evaluation of five surgical hand scrub preparations

Iodine revisited

Toxicity of Povidone-iodine to the ocular surface of rabbits

Experimental study on the toxicity of povidone-459 iodine solution in brain tissues of rabbits

Comparison of the effects of iodine and 462 iodide on thyroid function in humans

Chemical and microbiologic characteristics and toxicity of povidone-iodine solutions

Iodine toxicity in a patient treated by continuous 467 povidone-iodine mediastinal irrigation. The Annals of thoracic surgery

Fatal iatrogenic iodine toxicity in a nine-week 470 old infant

Fatal iodine toxicity following surgical debridement of a hip 472 wound: case report

Role of iodine in evolution and 475 carcinogenesis of thyroid, breast and stomach

Iodide 478 accumulation provides kelp with an inorganic antioxidant impacting atmospheric chemistry

A newly discovered 482 oxidant defence system and its involvement in the development of Aurelia aurita (Scyphozoa, Cnidaria): 483 reactive oxygen species and elemental iodine control medusa formation

Anti-inflammatory 486 properties of a liposomal hydrogel with povidone-iodine (Repithel) for wound healing in vitro

Iodine released from the wound dressing 489 Iodosorb modulates the secretion of cytokines by human macrophages responding to bacterial 490 lipopolysaccharide

delta-Iodolactones decrease epidermal growth factor-induced 493 proliferation and inositol-1,4,5-trisphosphate generation in porcine thyroid follicles--a possible 494 mechanism of growth inhibition by iodide

The role of iodine and delta-iodolactone in growth and apoptosis of 497 malignant thyroid epithelial cells and breast cancer cells

Antiproliferative/cytotoxic activity of molecular 500 iodine and iodolactones in various human carcinoma cell lines. No interfering with EGF-signaling, but 501 evidence for apoptosis

Molecular iodine 505 induces caspase-independent apoptosis in human breast carcinoma cells involving the mitochondria-506 mediated pathway. Date of Input: 5/6

Antineoplastic effect of iodine in mammary cancer: participation of 6-iodolactone (6-IL) and peroxisome 510 proliferator-activated receptors (PPAR)

Antiproliferative/cytotoxic effects of molecular 513 iodine, povidone-iodine and Lugol's solution in different human carcinoma cell lines

Adjuvant 516 Effect of Molecular Iodine in Conventional Chemotherapy for Breast Cancer

Uptake and gene expression with 519 antitumoral doses of iodine in thyroid and mammary gland: evidence that chronic administration has no 520 harmful effects. Date of Input: 3/10

Molecular iodine exerts antineoplastic effects by diminishing proliferation and 523 invasive potential and activating the immune response in mammary cancer xenografts

Theory on the evolutionary history of lamprey metamorphosis: role of 526 reproductive and thyroid axes

Cross-kingdom hormonal signaling: an insight from thyroid hormone 529 functions in marine larvae

Factors influencing the study of peroxidase-generated iodine 531 species and implications for thyroglobulin synthesis. Date of Input: 3/10